Translational Medicine and Oncologists Meet

Abs against myelin basic protein (MBP), cardiac myosine (CM) and thyroid Ags (TPO, T3 and T4) endowing with proteolytic activity (Ab-proteases) are of great value to monitor chronic auto-immune inflammation and to thus illustrate the evolution of either of the above-mentioned auto-immune disorders. Ab-proteases from MS, AIM and AIT patients exhibited specific proteolytic cleavage of MBP, CM and thyroid Ags (T3, T3, TPO), respectively The activity of the Ab-proteases markedly differs between: (i) the patients and healthy controls, and (ii) different clini-cal courses, to to predict transformation prior to changes of the clinical course. The activity of Ab-proteases was first registered at the subclinical stages 1-5 years (regardless to type of the dis-order) prior to the clinical illness. Some (12-24%) of the direct disease-related relatives are sero-positive for low-active Ab-proteases from which seropositive relatives established were being monitored for 2-3 years whilst demonstrating a stable growth of the Ab-associated proteolytic activity. We saw also low-active Ab-proteases in persons at MS-, AIM- and AIT-related risks (at the subclinical stages), and primary clinical, ultrasonic and MRT manifestations observed were coincided with the activity to have its mid-level reached. The activity of Ab-proteases would confirm a high subclinical and predictive value of the translational tools as applicable for person-alized monitoring protocols. Ab-proteases can be programmed and re-programmed to suit the needs of the body metabolism. Of tremendous value are Ab-proteases directly affecting the physiologic remodeling of tissues with multilevel architecture. Further studies on targeted Ab-mediated proteolysis may provide a supplementary tool for predicting exacerbations and thus the disability of the MS, AIM and AIT patients.